Quant Large and Mid Cap Fund
The scheme seeks to provide capital appreciation by investing in a portfolio of Large and Midcap companies.
Growthvine rating: 3/5 — ranked #13 of 41 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹114.92 (as of 2026-10-23) |
|---|
| AUM | ₹3,487 Cr |
|---|
| Expense ratio | 1.66% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ayusha Kumbhat |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| 5-year annualised return | 13.29% |
|---|
| Sharpe ratio | 0.43 |
|---|
| Standard deviation | 19.59% |
|---|
| Max drawdown | −53.45% |
|---|
| Alpha | 2.88 |
|---|
| Beta | 1.13 |
|---|
Over 5 years, captured 111.2% of NIFTY LargeMidcap 250's upside and 101.5% of its downside.
Market cap allocation
| Large cap | 39.8% |
|---|
| Mid cap | 52.9% |
|---|
| Small cap | 7.2% |
|---|
Concentration
| Top 5 holdings | 40.4% |
|---|
| Top 10 holdings | 62.2% |
|---|
| Total holdings | 23 |
|---|
| Index overlap | 4.1% |
|---|
| Active share | 95.9% |
|---|
Top holdings
- TREPS 01-Oct-2026 DEPO 10 — 21.9%
- Aurobindo Pharma Ltd. — 9.8%
- Lloyds Metals and Energy Limited — 9.7%
- Samvardhana Motherson International Limited — 8.0%
- Adani Enterprises Ltd. — 6.7%
- Adani Green Energy Limited — 6.2%
- Adani Power Limited — 5.5%
- Bharti Airtel Ltd. — 5.3%
- Glenmark Pharmaceuticals Ltd. — 4.0%
- Zydus Lifesciences Limited — 3.7%
Top sectors
- Derivatives — 14.4%
- Pharma & Biotech — 13.4%
- Energy — 13.3%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 0.4% | Q1 (Top) | #2 of 38 |
| 2025 | −2.0% | Q4 (Bottom) | #32 of 34 |
| 2024 | 17.8% | Q3 | #21 of 29 |
| 2023 | 32.2% | Q1 (Top) | #7 of 28 |
| 2022 | 13.0% | Q1 (Top) | #1 of 28 |